Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.

Genetic testing and molecular biomarkers - 1 May 2023

Aoullay Zineb, Smith Andrew, Slaoui Meriem, El Bouchikhi Ihssane, Ghazal Hassan, Al Idrissi Najib, Meddah Bouchra, Lynch Kara L, Cherrah Yahia, Wu Alan H B

Abstract excerpt

Background: There is extensive interindividual variability in response and tolerance to anticancer drugs. This heterogeneity provides a major limitation to the "rational" use of cytotoxic drugs, and it becomes a major problem in oncology giving a narrow therapeutic window with a vital risk. Among these anticancer drugs, irinotecan can cause dose-limiting toxicities, commonly diarrhea and neutropenia. Interaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Genotype

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Pancreatic Neoplasms

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 37257181
DOI: 10.1089/gtmb.2022.0109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.PMID 37257181Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.Semantic proximity Read ↗

Association of UGT1A1*6,*28 or ABCC2 c.3972C>T genetic polymorphisms with irinotecan induced toxicity in Asian cancer patients: Meta-analysisSemantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.Semantic proximity Read ↗

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.Semantic proximity Read ↗

Clinical and pharmacogenetic factors associated with irinotecan toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.